Business
Remdesivir study by World Health Organisation casts doubt, disputed by Gilead Sciences Inc – 7NEWS.com.au
The antiviral medication was one of the drugs used to treat US President Donald Trump after his COVID-19 diagnosis.
Gilead Sciences Inc has questioned the findings of a World Health Organisation (WHO) study that concluded its COVID-19 drug remdesivir does not help patients who have been admitted to hospital.
The American company told Reuters the data appeared inconsistent, the findings were premature and that other studies had validated the drugs benefits.
In a blow to one of the few drugs being used to treat people with COVID-19, the WHO said on Thursday its Solidarity trial had concluded that remdesivir a…
-
Noosa News17 hours agoYoung voices shape Sunshine Coast’s future
-
Business16 hours ago2 Low Cost Active ASX ETFs to consider
-
Noosa News16 hours agoSXSW Sydney Has Announced the First 40 Speakers That’ll Be Taking to the Stage at Its 2025 Conference
-
Business13 hours agoshould I buy hedged or unhedged ASX US-focused ETFs?